We canât show the full text here under this license. Use the link below to read it at the source.
Heart failure with preserved ejection fraction and metabolic dysfunction-associated steatotic liver disease: Twin challenges, one metabolic solution
Heart failure with normal pumping and fatty liver disease linked to metabolism: Two problems, one metabolic approach
AI simplified
Abstract
Heart failure with preserved ejection fraction (HFpEF) has become the most common type of heart failure.
- HFpEF is primarily associated with chronic low-grade inflammation and metabolic disorders.
- The coexistence of HFpEF and metabolic dysfunction-associated steatotic liver disease (MASLD) complicates clinical management due to overlapping metabolic issues.
- Sodium-glucose cotransporter 2 inhibitors have demonstrated potential benefits in treating both HFpEF and MASLD.
- Glucagon-like peptide-1 receptor agonists are under investigation for their possible advantages in managing MASLD.
- A comprehensive approach that integrates metabolic and cardiovascular care may be crucial for improving patient outcomes.
AI simplified